JPY1,425.00
4.04% today
Tokyo, Feb 05, 07:15 am CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Target price 2025 - Analyst rating & recommendation

Astellas Pharma Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
7%

Astellas Pharma Price Target

Target Price JPY1,894.29
Price JPY1,427.50
Potential
Number of Estimates 14
14 Analysts have issued a price target Astellas Pharma 2026 . The average Astellas Pharma target price is JPY1,894.29. This is higher than the current stock price. The highest price target is
JPY2,400.00 68.13%
register free of charge
, the lowest is
JPY1,400.00 1.93%
register free of charge
.
A rating was issued by 15 analysts: 7 Analysts recommend Astellas Pharma to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2026 of . Most analysts recommend the Astellas Pharma stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '24 2025
Estimates
Revenue Billion JPY 1,603.67 1,843.08
5.60% 14.93%
EBITDA Margin 20.95% 19.15%
18.68% 8.58%
Net Margin 1.06% 0.57%
83.41% 46.25%

13 Analysts have issued a sales forecast Astellas Pharma 2025 . The average Astellas Pharma sales estimate is

JPY1.8t
Unlock
. This is
4.00% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY1.9t 7.45%
Unlock
, the lowest is
JPY1.8t 1.27%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 JPY1.6t 5.60%
2025
JPY1.8t 14.93%
Unlock
2026
JPY1.9t 2.77%
Unlock
2027
JPY2.0t 6.03%
Unlock
2028
JPY1.9t 4.14%
Unlock
2029
JPY1.7t 10.01%
Unlock

10 Analysts have issued an Astellas Pharma EBITDA forecast 2025. The average Astellas Pharma EBITDA estimate is

JPY353b
Unlock
. This is
8.83% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
JPY452b 16.87%
Unlock
, the lowest is
JPY194b 50.00%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 JPY336b 14.13%
2025
JPY353b 5.08%
Unlock
2026
JPY408b 15.72%
Unlock
2027
JPY485b 18.68%
Unlock
2028
JPY511b 5.41%
Unlock
2029
JPY532b 4.13%
Unlock

EBITDA Margin

2024 20.95% 18.68%
2025
19.15% 8.58%
Unlock
2026
21.57% 12.64%
Unlock
2027
24.14% 11.91%
Unlock
2028
26.54% 9.94%
Unlock
2029
30.71% 15.71%
Unlock

5 Astellas Pharma Analysts have issued a net profit forecast 2025. The average Astellas Pharma net profit estimate is

JPY10.5b
Unlock
. This is
80.90% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY67.5b 23.20%
Unlock
, the lowest is
JPY-46.5b 184.97%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 JPY17.0b 82.49%
2025
JPY10.5b 38.48%
Unlock
2026
JPY159b 1,420.23%
Unlock
2027
JPY220b 38.26%
Unlock
2028
JPY236b 7.29%
Unlock
2029
JPY221b 6.34%
Unlock

Net Margin

2024 1.06% 83.41%
2025
0.57% 46.25%
Unlock
2026
8.40% 1,373.68%
Unlock
2027
10.95% 30.36%
Unlock
2028
12.25% 11.87%
Unlock
2029
12.75% 4.08%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Mar '24 2025
Estimates
Earnings Per Share JPY 9.50 5.84
82.49% 38.53%
P/E 254.11
EV/Sales 1.85

5 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

JPY5.84
Unlock
. This is
80.92% lower
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
JPY37.70 23.20%
Unlock
, the lowest is
JPY-26.00 184.97%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 JPY9.50 82.49%
2025
JPY5.84 38.53%
Unlock
2026
JPY88.84 1,421.23%
Unlock
2027
JPY122.83 38.26%
Unlock
2028
JPY131.79 7.29%
Unlock
2029
JPY123.43 6.34%
Unlock

P/E ratio

Current 48.54 45.92%
2025
254.11 423.51%
Unlock
2026
16.72 93.42%
Unlock
2027
12.09 27.69%
Unlock
2028
11.27 6.78%
Unlock
2029
12.03 6.74%
Unlock

Based on analysts' sales estimates for 2025, the Astellas Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.92 20.33%
2025
1.85 3.83%
Unlock
2026
1.80 2.70%
Unlock
2027
1.69 5.69%
Unlock
2028
1.77 4.32%
Unlock
2029
1.96 11.12%
Unlock

P/S ratio

Current 1.50 24.12%
2025
1.44 3.85%
Unlock
2026
1.40 2.70%
Unlock
2027
1.32 5.69%
Unlock
2028
1.38 4.32%
Unlock
2029
1.53 11.12%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today